New Diabetes Treatment Shows Promising Results in Landmark Trial

A novel therapy for type 2 diabetes, developed by researchers at the University of California, San Francisco, demonstrated significant improvements in blood sugar control and weight loss in a Phase III clinical trial, according to findings published in the New England Journal of Medicine on July 2, 2026.

What Is the New Diabetes Treatment?

The treatment, called GLP-1R/FGF21 dual agonist, targets two key metabolic pathways to regulate glucose levels and promote weight loss. Unlike traditional GLP-1 receptor agonists, which primarily focus on appetite suppression, this therapy combines mechanisms to enhance insulin sensitivity and fat metabolism, according to the study authors.

How Does It Work?

The drug activates both glucagon-like peptide-1 (GLP-1) and fibroblast growth factor 21 (FGF21) receptors, which are involved in glucose regulation and energy expenditure. By stimulating these pathways, the therapy reduces hepatic glucose production and increases fat breakdown, as explained by Dr. Emily Zhang, lead researcher at UCSF.

What Were the Trial Results?

In a 68-week trial involving 1,200 participants, the treatment reduced HbA1c levels by an average of 1.8%—a greater reduction than observed with standard GLP-1 agonists. Participants also lost an average of 12.5 kg (27.5 lbs), compared to 5 kg (11 lbs) with existing therapies, according to the study. Adverse effects were primarily mild gastrointestinal issues, with no significant safety concerns reported.

Why Is This Significant?

The dual-action approach addresses limitations of current diabetes medications, which often require combination therapies to achieve optimal outcomes. “This treatment could simplify management for patients who struggle with weight and blood sugar control,” said Dr. Michael Thompson, an endocrinologist not involved in the study. The results align with broader efforts to develop therapies that tackle both metabolic and cardiovascular risks associated with diabetes.

What Happens Next?

The researchers are seeking U.S. Food and Drug Administration (FDA) approval, with a decision expected by late 2027. If approved, the therapy could become a first-line treatment for patients with type 2 diabetes, particularly those with obesity. The study’s authors also plan to investigate its long-term effects on cardiovascular outcomes.

How Does It Compare to Existing Treatments?

Compared to semaglutide (Ozempic) and dulaglutide (Trulicity), the new therapy showed greater weight loss and HbA1c reduction in the trial. However, longer-term data is needed to confirm sustained efficacy and safety. The FDA has previously approved FGF21 agonists for rare genetic disorders, but this is the first dual-action therapy for common diabetes care.

What Are the Next Steps for Patients?

Until regulatory approval, the treatment remains in clinical trials. Patients should consult their healthcare providers about existing options, such as lifestyle modifications, metformin, or GLP-1 agonists. Researchers emphasize that the therapy is not a substitute for insulin in patients with advanced diabetes.

For now, the study represents a major step forward in diabetes care, offering hope for a more effective, single-therapy approach to managing a condition affecting over 537 million people globally, according to the International Diabetes Federation.